Swedish Orphan Biovitrum (Sobi) | Sustainability Performance
Swedish Orphan Biovitrum AB (publ) is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care.
1951
Sweden
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$25M - 100M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#16
Overallⓘ#2
in Swedenⓘ#1
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
TargetsSDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Leading
Leading
Leading
Intensity
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Industry Benchmark
88.1
B/M 111.2
Powered by illuminem and GIST Impact
Controversy level
- Sobi faced criticism for high pricing of rare disease treatments that limit patient access in smaller European healthcare markets.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.